Prophylactic colony-stimulating factors in children receiving myelosuppressive chemotherapy: A meta-analysis of randomized controlled trials

Cancer Treatment Reviews

Volumn 32, Issue 4, 2006, Pages 289-303

  Wittman, Brenda ^a   Horan, John ^b   Lyman, Gary H ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Colony stimulating factors; Febrile neutropenia; Infection

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; ASPARTIC ACID; CISPLATIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DACTINOMYCIN; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROXYUREA; IFOSFAMIDE; LOMUSTINE; MERCAPTOPURINE; METHYLPREDNISOLONE; MITOXANTRONE; NYSTATIN; PLACEBO; PREDNISOLONE; PROCARBAZINE; TENIPOSIDE; TIOGUANINE; VINCRISTINE; ANTIINFECTIVE AGENT; COLONY STIMULATING FACTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; BONE PAIN; CHEMOTHERAPY INDUCED EMESIS; CHILDHOOD CANCER; CHILDHOOD LEUKEMIA; CLINICAL TRIAL; DISEASE DURATION; DRUG USE; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; HOSPITALIZATION; HUMAN; INFECTION; INFORMATION RETRIEVAL; LENGTH OF STAY; MEDLINE; META ANALYSIS; NONHODGKIN LYMPHOMA; PNEUMOCYSTIS PNEUMONIA; PRIMARY PREVENTION; REVIEW; SOLID TUMOR; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; BONE MARROW; CHEMOPROPHYLAXIS; CHILD; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; NEUTROPENIA; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TIME;

ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; BONE MARROW; CHEMOPREVENTION; CHILD; COLONY-STIMULATING FACTORS; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HOSPITALIZATION; HUMANS; NEUTROPENIA; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; TIME FACTORS;

EID: 33746919601     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2006.03.002     Document Type: Review

References (128)

1. Lyman G., and Nicole K. Epidemiology of febrile neutropenia. Support Cancer Ther 1 1 (2003) 1-13
2. Lehrnbecker T. Hematologic growth factors in children with neutropenia. Br J Haematol 116 (2002) 28-56
3. American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. J Clin Oncol 12 (1994) 2471-2508
4. American Society of Clinical Oncology. Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. J Clin Oncol 14 (1996) 1957-1960
5. Ozer H., Armitage J.C., Bennett C.L., et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines - American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 18 (2000) 3558-3585
6. Welte K., Gabrilove J., Bronchud M.H., et al. Filgrastim (r-metHuG-CSF): the first 10 years. Blood 88 6 (1996) 1907-1929
7. Bergmann L., Karakas T., Knuth A., et al. Recombinant human granulocyte-macrophage colony-stimulating factor after combined chemotherapy in high-grade non-Hodgkin's lymphoma - a randomised pilot study. Eur J Cancer 31A 13-14 (1995) 2164-2168
8. Clark O.A., Lyman G., Castro A.A., et al. Colony stimulating factors for chemotherapy induced febrile neutropenia. Cochrane Database Syst Rev 3 (2003) CD003039
9. Crawford J., Ozer H., Stoller R., et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325 (1991) 164-170
10. Gerhartz H., Engelhard M., Meusers P., et al. Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas. Blood 82 8 (1993) 2329-2339
11. Kern W., Aul C., Maschmeyer G., et al. Granulocyte colony-stimulating factor shortens duration of critical neutropenia and prolongs disease-free survival after sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy for refractory and relapsed acute myeloid leukemia. Ann Hematol 77 (1998) 115-122
12. Lyman G. Balancing the benefits and costs of colony-stimulating factors: a current perspective. Semin Oncol 30 4 Supp 13 (2003) 10-17
13. Lyman G., Kuderer N.M., and Balducci L. Cost-benefit analysis of granulocyte colony-stimulating factor in the management of elderly cancer patients. Curr Opin Hematol 9 (2002) 207-214
14. Lyman G., Lyman C.G., Sanderson R.A., et al. Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. J Natl Cancer Inst 85 6 (1993) 88-93
15. Lyman G., Kuderer N.M., and Djuibegovic B. Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. Am J Med 112 (2002) 406-411
16. Lyman G., and Balducci L. Update of the economic analyses of the use of the colony-stimulating factors. Curr Opin Hematol 6 3 (1999) 145
17. Maher D., Lieschke G.J., Green M., et al. Filgrastim in patients with chemotherapy-induced febrile neutropenia: a double-blind, placebo-controlled trial. Ann Intern Med 121 (1994) 492-501
18. Ohno R., Miyawaki S., Hatake K., et al. Human urinary macrophage colony-stimulating factor reduces the incidence and duration of febrile neutropenia and shortens the period required to finish three courses of intensive consolidation therapy in acute myeloid leukemia: a double-blind controlled study. J Clin Oncol 15 8 (1997) 2954-2965
19. Pettengell R., Gumey H., Radford J.A., et al. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-hodgkin's lymphoma: a randomized controlled trial. Blood 80 (1992) 1430-1436
20. Ravaud A., Chevreau C., Cany L., et al. Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial. J Clin Oncol 16 9 (1998) 2930-2936
21. Shaffer D.W., Smith L.S., Burris H.A., et al. A randomized phase I trial of chronic oral etoposide with or without granulocyte-macrophage colony-stimulating factor in patients with advanced malignancies. Cancer Res 53 (1993) 5929-5933
22. Trillet-Lenoir V., Green J., Manegold C., et al. Recombinant granulocyte colony-stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 29 (1993) 319-324
23. Vellenga E., Uyl-de-Groot C., deWit R., et al. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia. J Clin Oncol 14 2 (1996) 619-627
24. Yau J., Neidhart J.A., Triozzi P., et al. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating-factor support for dose-intensive cyclophosphamide, etoposide, and cisplatin. Am J Hematol 51 (1996) 289-295
25. Zittoun R., Suciu S., Mandelli F., et al. Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the european organization for research and treatment of cancer leukemia cooperative group. J Clin Oncol 14 7 (1996) 2150-2159
26. Marsoni S., Ungerleider R.S., Hurson S.B., et al. Tolerance to antineoplastic agents in children and adults. Cancer Treat Rep 69 (1985) 1263-1266
27. Hann I., Viscoli C., Paesmans M., et al. A comparison of outcome from febrile neutropenic episodes in children compared with adults: results from four EORTC studies. Br J Haematol 99 (1997) 580-588
28. Burdach S. Molecular regulation of hematopoietic cytokines: implications and indications for clinical use in pediatric oncology. Med Pediatr Oncol Suppl. 2 (1992) 0-17
29. Burdach S., Muschenich M., Josephs W., et al. Granulocyte-macrophage-colony stimulating factor for prevention of neutropenia and infections in children and adolescents with solid tumors. Cancer 76 3 (1995) 510-516
30. Calderwood S., Romeyer F., Blanchette V., et al. Concurrent RhGM-CSF does not offset myelosuppression from intensive chemotherapy: randomized placebo-controlled study in childhood acute lymphoblastic leukemia. Am J Hematol 47 (1994) 27-32
31. Clarke V., Dunstan F.D., and Webb D.K. Granulocyte colony-stimulating factor ameliorates toxicity of intensification chemotherapy for acute lymphoblastic leukemia. Med Pediatr Oncol 32 5 (1999) 331-335
32. Dibenedetto S.P., Ragusa R., Ippolito A.M., et al. Assessment of the value of treatment with granulocyte colony-stimulating factor in children with acute lymphoblastic leukemia: a randomized clinical trial. Eur J Haematol 55 (1995) 93-96
33. Heath J.A., Steinherz P.G., Altman A., et al. Human granulocyte colony-stimulating factor in children with high risk acute lymphoblastic leukemia: A Children's Cancer Group Study. J Clin Oncol 21 8 (2003) 1612-1617
34. Kalmanti M., Lydaki E., Dimitriou H., et al. Effect of granulocyte colony-stimulating factor on chemotherapy-induced neutropenia in children with cancer. Pediatr Hematol Oncol 11 (1994) 147-155
35. Laver J., Amylon M., Desai S., et al. Randomized trial of r-metHu granulocyte colony-stimulating factor in an intensive treatment for T-cell leukemia and advanced-stage lymphoblastic lymphoma of childhood: A Pediatric Oncology Group Pilot Study. J Clin Oncol 16 2 (1998) 522-526
36. Little M.A., Morland B., Chisholm J., et al. A randomized study of prophylactic G-CSF following MRC UKALL XI intensification regimen in childhood ALL and T-NHL. Med Pediatr Oncol 38 (2002) 98-103
37. Michel G., Landman-Parker J., Auclerc M.F., et al. Use of recombinant human granulocyte colony-stimulating factor to increase chemotherapy dose-intensity: a randomized trial in very high-risk childhood acute lymphoblastic leukemia. J Clin Oncol 18 7 (2000) 1517-1524
38. Michon J.M., Hartmann O., Bouffet E., et al. An open-label, multicentre, randomised phase 2 study of recombinant human granulocyte colony-stimulating factor (Filgrastim) as an adjunct to combination chemotherapy in pediatric patients with metastatic neuroblastoma. Eur J Cancer 34 7 (1998) 1063-1069
39. Patte C., Laplanche A., Bertozzi A.I., et al. Granulocyte colony-stimulating factor in induction treatment of children with non-hodgkin's lymphoma: a randomized study of the French Society of Pediatric Oncology. J Clin Oncol 20 2 (2002) 441-448
40. Pui C.H., Boyett J.M., Hughes W.T., et al. Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. N Engl J Med 336 25 (1997) 1781-1787
41. Riikonen P., Rahiala J., Salonvaara M., et al. Prophylactic administration of granulocyte colony-stimulating factor (Filgrastim) after conventional chemotherapy in children with cancer. Stem Cells 13 (1995) 289-294
42. Van Pelt L.J., de Craen A.J., Langeveld N.E., et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) ameliorates chemotherapy-induced neutropenia in children with solid tumors. Pediatr Hematol Oncol 14 (1997) 539-545
43. Welte K., Reiter A., Mempel K., et al. A randomized phase-III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Blood 87 8 (1996) 3143-3150
44. Wexler L.H., Weaver-McClure L., Steinberg S.M., et al. Randomized trial of recombinant human granulocyte-macrophage colony-stimulating factor in pediatric patients receiving intensive myelosuppressive chemotherapy. J Clin Oncol 14 3 (1996) 901-910
45. Anaissie E., Vartivarian S., Bodey G.P., et al. Randomized comparison between antibiotics alone and antibiotics plus granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived) in cancer patients with fever and neutropenia. Am J Med 10 (1996) 17-23
46. Ayan I., Kebudi R., Dogan S., et al. Granulocyte colony-stimulating factor in neutropenic pediatric solid tumor patients following chemotherapy. Pediatr Hematol Oncol 13 (1996) 417-424
47. Fink F.-M., Maurer-Dengg K., Fritsch G., et al. Recombinant human granulocyte-macrophage colony-stimulating factor in septic neutropenic pediatric cancer patients: detection of circulating hematopoietic precursor cells correlates with rapid granulocyte recovery. Med Pediatr Oncol 25 (1995) 365-371
48. Liang D.C., Chen S.H., and Lean S.F. Role of granulocyte colony-stimulating factor as adjunct therapy for septicemia in children with acute leukemia. Am J Hematol 48 (1995) 76-81
49. Mayordomo F., Rivera M.T., Diaz-Puente P., et al. improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. J Natl Cancer Inst 87 11 (1995) 803-808
50. Mitchell P., Morland B., Stevens M., et al. Granulocyte colony-stimulating factor in established febrile neutropenia: a randomized study of pediatric patients. J Clin Oncol 15 3 (1997) 1163-1670
51. Riikonen P., Saarinen U.M., Makipernaa A., et al. Recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of febrile neutropenia: a double blind placebo-controlled study in children. Pediatr Infect Dis J 13 (1994) 197-202
52. Abrahamsen T.G., Lange B.J., Packer R.J., et al. A phase I and II trial of dose-intensified cyclophosphamide and GM-CSF in pediatric malignant brain tumors. J Pediatr Hematol Oncol 17 2 (1995) 134-139
53. Alexander S.W., Wade K.C., Hibberd P.L., et al. Evaluation of risk prediction criteria for episodes of febrile neutropenia in children with cancer. J Pediatr Hematol Oncol 24 1 (2002) 38-42
54. Alonzo A., Kobrinsky N.L., Aledo A., et al. Impact of granulocyte colony-stimulating factor use during induction for acute myelogenous leukemia in children: a report from the Children's Cancer Group. J Pediatr Hematol Oncol 24 8 (2002) 627-635
55. Bracho F., Krailo M.D., Shen V., et al. A phase I clinical, pharmacological, and biological trial of interleukin 6 plus granulocyte-colony stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent/refractory solid tumors: enhanced hematological responses but a high incidence of grade III/IV constitutional toxicities. Clin Cancer Res 7 (2001) 58-67
56. Cairo M., Krailo M.D., Weinthal J.A., et al. A phase I study of granulocyte-macrophage-colony stimulating factor/interleukin-3 fusion protein (PIXY321) following ifosfamide, carboplatin,and etoposide therapy for children with recurrent or refractory solid tumors. Cancer 83 7 (1998) 1449-1460
57. Chen S., Liang D.C., and Liu H.C. High-dose cytarabine-containing chemotherapy with or without granulocyte colony-stimulating factor for children with acute leukemia. Am J Hematol 58 1 (1998) 20-23
58. Deb G., Donfrancesco A., Sio L.D., et al. Shortened time to recovery from chemotherapy induced neutropenia in pediatric patients with high-dose combined cytokines. Anticancer Res 18 1B (1998) 489-492
59. Householder S., Rackoff W., Goldman J., and Breitfeld P. A case-control retrospective study of the efficacy of granulocyte-colony-stimulating factor in children with neuroblastoma. Am J Pediatr Hematol Oncol 16 2 (1994) 132-137
60. Jones C., Shaw P., and Stevens M. Use of granulocyte colony stimulating factor to reduce toxicity of super-VAC chemotherapy in advanced solid tumors in childhood. Med Pediatr Oncol 25 (1995) 84-89
61. Kushner B., Heller G., Kramer K., et al. Granulocyte-colony stimulating factor and multiple cycles of strongly myelosuppressive alkylator-based combination chemotherapy in children with neuroblastoma. Cancer 89 10 (2000) 2122-2130
62. Luksch R., Massimino M., Cefalo G., et al. Effects of recombinant human granulocyte-macrophage colony-stimulating factor in an intensive treatment program for children with Ewing's sarcoma. Haematologica 86 (2001) 753-760
63. Marina N., Shema S.J., Bowman L.C., et al. Failure of granulocyte-macrophage colony-stimulating factor to reduce febrile neutropenia in children with recurrent solid tumors treated with ifosfamide, carboplatin, and etoposide chemotherapy. Med Pediatr Oncol 23 (1994) 328-334
64. McCowage G.B., White L., Carpenter P., et al. Granulocyte-macrophage colony-stimulating factor in association with high-dose chemotherapy (VETOPEC) for childhood solid tumors: a report from the Australia and New Zealand Children's Cancer Study Group. Med Pediatr Oncol 29 2 (1997) 108-114
65. Okamura J., Yokoyama M., Tsukimoto I., et al. Treatment of chemotherapy-induced neutropenia in children with subcutaneously administered recombinant human granulocyte colony-stimulating factor. Pediatr Hematol Oncol 9 (1992) 199-207
66. Rahiala J., Perkkio M., Riikonen P., et al. Prospective and randomized comparison of early versus delayed prophylactic administration of granulocyte colony-stimulating factor (Filgrastim) in children with cancer. Med Pediatr Oncol 32 5 (1999) 326-330
67. Saarinen U., Hovi L., Riikonen P., et al. Recombinant human granulocyte-macrophage colony-stimulating factor in children with chemotherapy-induced neutropenia. Med Pediatr Oncol 20 (1992) 489-496
68. Seibel N.L., Blaney S.M., O'Brien M., et al. Phase I trial of docetaxel with filgrastim support in pediatric patients with refractory solid tumors: a Collaborative Pediatric Oncology Branch, National Cancer Institute and Children's Cancer Group Trial. Clin Cancer Res 5 (1999) 733-737
69. Womer R.B., Daller R.T., Fenton J.G., et al. Granulocyte colony stimulating factor permits dose intensification by interval compression in the treatment of Ewing's sarcomas and soft tissue sarcomas in children. Eur J Cancer 36 (2000) 87-94
70. Asano S. Human granulocyte colony-stimulating factor: its basic aspects and clinical applications. Am J Pediatr Hematol Oncol 13 4 (1991) 400-413
71. Bessmertny O., and Cairo M. Prophylactic use of myelopoietic growth factors in children after myelosuppressive chemotherapy: does it pay. J Pediatr Hematol Oncol 25 6 (2003) 435-440
72. Furman W., and Crist W. Biology and clinical applications of hemopoietins in pediatric practice. Pediatrics 90 5 (1992) 716-728
73. Furman W., and Crist W. Potential uses of recombinant human granulocyte-macrophage colony-stimulating factor in children. Am J Pediatr Hematol Oncol 13 4 (1991) 388-399
74. Furman W., Fairclough D.L., Huhn R.D., et al. Therapeutic effects and pharmacokinetics of recombinant human granulocyte-macrophage colony-stimulating factor in childhood cancer patients receiving myelosuppressive chemotherapy. J Clin Oncol 9 6 (1991) 1022-1028
75. Furman W.L., Fairclough D., Cain A.M., et al. Use of GM-CSF in children after high-dose chemotherapy. Med Pediatr Oncol 2 Suppl. 2 (1992) 26-30
76. Holldack J., Burdach S., Eisberd A., et al. Biology and pharmacology of hematopoietic growth factors. Med Pediatr Oncol 2 Supp 2 (1992) 2-9
77. Laver J., and Moore M. Clinical use of recombinant human haematopoietic growth factors. J Natl Cancer Inst 81 18 (1989) 1370-1382
78. Levine J., and Boxer L. Clinical applications of hematopoietic growth factors in pediatric oncology. Curr Opin Hematol 9 (2002) 222-227
79. Lifton R., and Bennett J.M. Clinical use of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in neutropenia associated with malignancy. Hematol Oncol Clin N Am 10 4 (1996) 825-839
80. Ottmann O., and Hoelzer D. Growth factors in the treatment of acute lymphoblastic leukemia. Leuk Res 22 (1998) 1171-1178
81. Schaison G., Eden O.B., Henze G., et al. Recommendations on the use of colony-stimulating factors in children: conclusions of a European panel. Eur J Pediatr 157 (1998) 955-966
82. Sung L., Nathan P.C., Lange B.J., et al. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials. J Clin Oncol 22 (2002) 3350-3556
83. Clark D., and Neidhart J. Granulocyte-macrophage colony-stimulating factor with dose-intensified treatment of cancer. Sem Hematol 29 4, Supp 3 (1992) 27-32
84. Mirro J., Hurwitz C.A., Behm F.G., et al. Effects of recombinant human hematopoietic growth factors on leukemic blasts from children with acute myeloblastic or lymphoblastic leukemia. Leukemia 7 7 (1993) 1026-1033
85. Ohno R. Granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor and macrophage colony-stimulating factor in the treatment of acute myeloid leukemia and acute lymphoblastic leukemia. Leuk Res 22 (1998) 1143-1154
86. Parsons S., Mayer D.K., Alexander S.W., et al. Growth factor practice patterns among pediatric oncologists: results of a 1998 Pediatric Oncology Group Survey. J Pediatr Hematol Oncol 22 3 (2000) 227-241
87. Parsons S. Oncology practice patterns in the use of hematopoietic growth factors. Curr Opin Pediatr 12 (2000) 10-17
88. Sprikkelman A., de Wolf J., and Vellenga E. The application of hematopoietic growth factors in drug-induced agranulocytosis: a review of 70 cases. Leukemia 8 12 (1994) 2031-2036
89. Yim J., MAtuszewski K.A., Vermeulen L.C., et al. Surveillance of colony-stimulating factor use in US academic health centers. Ann Pharmacother 29 (1995) 475-481
90. Hartmann L., Tschetter L.K., Habermann T.M., et al. Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia. N Engl J Med 336 25 (1997) 1776-1780
91. Moriyama Y., Takahashi M., Kaku K., et al. Effect of granulocyte-macrophage colony-stimulating factor on chemotherapy-induced granulocytopenia in patients with malignancies. Acta Haematol 89 (1993) 70-75
92. Serrone L., Zeuli M., Gamucci T., et al. A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas: a novel sequential schedule. Cancer Chemother Pharmacol 47 (2001) 206-210
93. Usuki K., Urabe A., Masaoka T., et al. Efficacy of granulocyte colony-stimulating factor in the treatment of acute myelogenous leukaemia: a multicentre randomized study. Br J Haematol 116 (2002) 103-112
94. Fossa S., Kaye S.B., Mead G.M., et al. Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. J Clin Oncol 16 2 (1998) 716-724
95. Harousseau J.L., Witz B., Lioure B., et al. Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: results of a randomized trial of the Groupe Ouest-Est Leucemies Aigues Myeloblastiques. J Clin Oncol 18 4 (2000) 780-787
96. Lowenberg B., Boogaerts M.A., Paenen S.M., et al. Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia. J Clin Oncol 15 12 (1997) 3496-3506
97. Neidhart J.A., Mangalik A., Stidley C.A., et al. Dosing regimen of granulocyte-macrophage colony-stimulating factor to support dose-intensive chemotherapy. J Clin Oncol 10 9 (1992) 1460-1469
98. Neidhart J.A., Kohler W., Stidley C., et al. Granulocyte colony-stimulating factor stimulates recovery of granulocytes in patients receiving dose-intensive chemotherapy without bone marrow transplantation. J Clin Oncol 7 11 (1989) 1685-1692
99. Ohno R., Tomonaga M., Kobayashi T., et al. Effect of granulocyte colony-simulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N Engl J Med 323 13 (1990) 871-877
100. Channa J., and Hashmi K.Z. Role of recombinant granulocyte-macrophage colony-stimulating factors in reducing the duration of neutropenia. J Physicians Surg Pak 12 (2002) 538-541
101. Bennett C.L., Stinson T.J., Lane D., et al. Cost analysis of Filgrastim for the prevention of neutropenia in pediatric T-cell leukemia and advanced lymphoblastic lymphoma: a case for prospective economic analysis in cooperative group trials. Med Pediatr Oncol 34 (2000) 92-96
102. Cairo M.S. Myelopoietic growth factors after stem cell transplantation: does it pay. J Pediatr Hematol Oncol 23 1 (2001) 2-6
103. Delorme J., Badin S., LeCorroller A.G., et al. Economic evaluation of recombinant human granulocyte colony-stimulating factor in very high-risk childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 25 6 (2003) 441-444
104. Parsons S.K., Levine K.J., Hoorntje L.E., et al. Impact of pharmacy practices on the cost of colony-stimulating factor use in pediatric stem cell transplantation: an institution-based analysis. J Pediatr Hematol Oncol 23 1 (2001) 19-24
105. Rubino C., Laplanche A., Patte C., et al. Cost-minimization analysis of prophylactic granulocyte colony-stimulating factor after induction chemotherapy in children with non-Hodgkin's lymphoma. J Natl Cancer Inst 10 (1998) 750-755
106. Uyl-de-Groot C.A., Vellenga E., and Rutten F.F.H. An economic model to assess the savings from a clinical application to haematopoietic growth factors. Eur J Cancer 32A 1 (1996) 57-62
107. Dolgopolov I., Andreeva L., Yankelevich M., et al. Delayed introduction of G-CSF after chemotherapy does not affect peripheral blood stem cell yield and engraftment kinetics in children with high-risk malignancies: retrospective study of 45 cases. Am J Hematol 73 (2003) 225-259
108. Fukuda M., Kojima S., Matsumoto K., et al. Autotransplantation of peripheral blood stem cells mobilized by chemotherapy and recombinant human granulocyte colony-stimulating factor in childhood neuroblastoma and non-Hodgkin's lymphoma. Br J Haematol 80 (1992) 327-331
109. Goldman S., Bracho F., Davenport V., et al. Feasibility study of IL-11 and granulocyte colony-stimulating factor after myelosuppressive chemotherapy to mobilize peripheral blood stem cells from heavily pretreated patients. J Pediatr Hematol Oncol 23 5 (2001) 300-305
110. Saarinen U., Hovi L., Juvonen E., et al. Granulocyte-colony-stimulating factor after allogeneic and autologous bone marrow transplantation in children. Med Pediatr Oncol 26 (1996) 380-386
111. Bonig H., Silbermann S., Weller S., et al. Glycosylated vs. non-glycosylated granulocyte colony-stimulating factor (G-CSF) - results of a prospective randomized monocentre study. Bone Marrow Transplant 28 (2001) 259-264
112. Furman W., Luo X., Marina N., et al. Comparison of cytokines in children with recurrent solid tumors treated with intensive therapy. J Pediatr Hematol Oncol 20 1 (1998) 62-68
113. Sturgill M., Huhn R.D., Drachtman J.H., et al. Pharmacokinetics of intravenous recombinant human granulocyte colony-stimulating factor (rhG-CSF) in children receiving myelosuppressive cancer chemotherapy: clearance increases in relation to absolute neutrophil count with repeated dosing. Am J Hematol 54 (1997) 124-130
114. Stute N., Santana V.M., Rodman J.H., et al. Pharmacokinetics of subcutaneous recombinant human granulocyte colony-stimulating factor in children. Blood 79 11 (1992) 2849-2854
115. Toner G., Shapiro J.D., Laidlaw C.R., et al. Low-dose versus standard-dose lenograstim prophylaxis after chemotherapy: a randomized, crossover comparison. J Clin Oncol 16 12 (1998) 3874-3879 1998 December
116. Cairo M., Shen V., Krailo M.D., et al. Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a Children's Cancer Group Report. J Pediatr Hematol Oncol 23 1 (2001)
117. Frisch J., Ganser A., Haelzer D., et al. Interleukin-3 and granulocyte-macrophage colony-stimulating factor in combination: clinical implication. Med Pediatr Oncol 2 (1992) 34-37
118. Saarinen-Pihkala U.M., Lanning M., Perkkio M., et al. Granulocyte-macrophage colony-stimulating factor support in therapy of high-risk acute lymphoblastic leukemia in children. Med Pediatr Oncol 34 5 (2000) 319-327
119. Kearns C., Wang W.C., Stute N., et al. Disposition of recombinant human granulocyte colony-stimulating factor in children with severe chronic neutropenia. J Pediatr 123 3 (1993) 471-479
120. Valent P., Sillaber C., Geissler K., et al. Treatment of de novo acute myelogenous leukemia with recombinant granulocyte macrophage colony-stimulating factor in combination with standard induction chemotherapy: effect of granulocyte macrophage colony-stimulating factor on white blood cell counts. Med Pediatr Oncol 2 Suppl 2 (1992) 18-22
121. Moher D., Schultz K.F., and Altman D.G. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Int Med 144 8 (2001) 657-661
122. Gavaghan D.J., Moore A.R., and McQay H.J. An evaluation of homogeneity tests in meta-analysis in pain using simulations of patient data. Pain 85 (2000) 415-424
123. Peto R., Collins R., and Gray R. Large-scale randomized evidence: large, simple trials and overviews of trials. J Clin Epidemiol 48 (1995) 23-40
124. Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. (1988), Lawrence Earlbaum Associates, Hillsdale (NJ)
125. Higgins J.P.T., and Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stats Med 21 (2002) 1539-1558
126. Fleiss J. The statistical basis of meta-analysis. Stat Methods Med Res 2 (1993) 121-145
127. Yusuf S., Wittes J., Probstfield J., and Tyroler H.A. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. J Am Med Assoc 266 (1991) 93-98
128. Altman D.G., and Bland J.M. Interaction revisited: the difference between two estimates. Brit Med J 326 (2003) 219